JP7702952B2 - Ｃｄ１６３抗体または結合タンパク質 - Google Patents

Ｃｄ１６３抗体または結合タンパク質 Download PDF

Info

Publication number
JP7702952B2
JP7702952B2 JP2022539134A JP2022539134A JP7702952B2 JP 7702952 B2 JP7702952 B2 JP 7702952B2 JP 2022539134 A JP2022539134 A JP 2022539134A JP 2022539134 A JP2022539134 A JP 2022539134A JP 7702952 B2 JP7702952 B2 JP 7702952B2
Authority
JP
Japan
Prior art keywords
heavy chain
antibody
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022539134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508674A (ja
JP2023508674A5 (https=
JPWO2021130502A5 (https=
Inventor
チャールズ オーウェン
ハフィド アブデラーリ ベンチャオウイ
バーカード クリスティーン テイト
Original Assignee
エコ アニマルヘルス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エコ アニマルヘルス リミテッド filed Critical エコ アニマルヘルス リミテッド
Publication of JP2023508674A publication Critical patent/JP2023508674A/ja
Publication of JP2023508674A5 publication Critical patent/JP2023508674A5/ja
Publication of JPWO2021130502A5 publication Critical patent/JPWO2021130502A5/ja
Application granted granted Critical
Publication of JP7702952B2 publication Critical patent/JP7702952B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022539134A 2019-12-24 2020-12-24 Ｃｄ１６３抗体または結合タンパク質 Active JP7702952B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1919294.7 2019-12-24
GBGB1919294.7A GB201919294D0 (en) 2019-12-24 2019-12-24 Antibodies or binding proteins
PCT/GB2020/053370 WO2021130502A1 (en) 2019-12-24 2020-12-24 Cd163 antibodies or binding proteins

Publications (4)

Publication Number Publication Date
JP2023508674A JP2023508674A (ja) 2023-03-03
JP2023508674A5 JP2023508674A5 (https=) 2023-10-24
JPWO2021130502A5 JPWO2021130502A5 (https=) 2023-10-24
JP7702952B2 true JP7702952B2 (ja) 2025-07-04

Family

ID=69322779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539134A Active JP7702952B2 (ja) 2019-12-24 2020-12-24 Ｃｄ１６３抗体または結合タンパク質

Country Status (13)

Country Link
US (1) US20230203185A1 (https=)
EP (1) EP4081542A1 (https=)
JP (1) JP7702952B2 (https=)
KR (1) KR20220119147A (https=)
CN (1) CN121873247A (https=)
BR (1) BR112022012362A2 (https=)
CL (1) CL2022001706A1 (https=)
CO (1) CO2022010294A2 (https=)
DO (2) DOP2022000136A (https=)
GB (1) GB201919294D0 (https=)
MX (1) MX2022007957A (https=)
PE (1) PE20230384A1 (https=)
WO (1) WO2021130502A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR129879A1 (es) * 2022-07-08 2024-10-09 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
GB202214979D0 (en) * 2022-10-11 2022-11-23 Eco Animal Health Ltd Binding protein
WO2024156888A1 (en) * 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119569865B (zh) * 2024-12-20 2025-10-10 西北农林科技大学 一种防治猪繁殖与呼吸障碍综合征病毒感染的混合制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018525000A (ja) 2015-08-06 2018-09-06 ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリＴｈｅ Ｃｕｒａｔｏｒｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｓｓｏｕｒｉ 改変ｃｄ１６３遺伝子を有する病原体抵抗性動物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11160260B2 (en) * 2018-04-17 2021-11-02 The Curators Of The University Of Missouri Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018525000A (ja) 2015-08-06 2018-09-06 ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリＴｈｅ Ｃｕｒａｔｏｒｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｓｓｏｕｒｉ 改変ｃｄ１６３遺伝子を有する病原体抵抗性動物

Also Published As

Publication number Publication date
US20230203185A1 (en) 2023-06-29
JP2023508674A (ja) 2023-03-03
CA3162664A1 (en) 2021-07-01
PE20230384A1 (es) 2023-03-06
EP4081542A1 (en) 2022-11-02
DOP2022000136A (es) 2022-11-30
DOP2025000290A (es) 2026-02-26
CL2022001706A1 (es) 2023-05-26
KR20220119147A (ko) 2022-08-26
BR112022012362A2 (pt) 2022-09-06
GB201919294D0 (en) 2020-02-05
CO2022010294A2 (es) 2022-10-31
MX2022007957A (es) 2022-10-07
WO2021130502A1 (en) 2021-07-01
CN121873247A (zh) 2026-04-17
CN115151569A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
JP7702952B2 (ja) Ｃｄ１６３抗体または結合タンパク質
TW201922792A (zh) Cd96 抗體、其抗原結合片段及醫藥用途
US11725063B2 (en) Antibodies against HPA-1a
US20240376180A1 (en) Human recombinant monoclonal antibody against sars-cov-2 spike glycoprotein
JP2025506172A (ja) コロナウイルスを広く標的とするヒトモノクローナル抗体
TW201915022A (zh) Ｉｌ－５抗體、其抗原結合片段及醫藥用途
Isaacs et al. A nanobody-based therapeutic targeting Nipah virus limits viral escape
CN113698487B (zh) 抗人ace2单克隆抗体及其应用
CN115151569B (zh) Cd163抗体或结合蛋白
CA3162664C (en) Cd163 antibodies or binding proteins
US20260085129A1 (en) Cd163 binding protein
CA2954687A1 (en) Substances and methods for the use in prevention and/or treatment in huntington's disease
EP3833442A2 (en) Antibodies that bind cd277 and uses thereof
CN106687475A (zh) 用于预防和/或治疗亨廷顿氏病的物质和方法
US20250304659A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 1 (SARS-CoV-1)
Coelho Isolation of human recombinant antibodies anti-SARS-CoV-2 by synthetic methods
WO2023178182A1 (en) Compositions and methods for detection and treatment of coronavirus infection
CN116419972A (zh) 抗SARS-CoV-2抗体及其应用
WO2023145874A1 (ja) コロナウイルスに対する新規なモノクローナル抗体
CN118496359A (zh) 一种抗Siglec-15抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231016

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250624

R150 Certificate of patent or registration of utility model

Ref document number: 7702952

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150